Platelet Factor 4, β-Thromboglobulin and Thrombospondin Levels in Type I Diabetes Mellitus Patients

1994 ◽  
Vol 22 (2) ◽  
pp. 90-94 ◽  
Author(s):  
M Bayraktar ◽  
S Dündar ◽  
S Kirazli ◽  
F Teletar
Keyword(s):  
Diabetes Mellitus ◽  
Type I Diabetes ◽  
Platelet Factor 4 ◽  
Type I Diabetes Mellitus ◽  
Control Group ◽  
Diabetic Patients ◽  
Type I ◽  
Platelet Factor ◽  
Release Reaction

The proteins β-thromboglobulin, platelet factor 4 and thrombospondin are stored in platelet α-granules and released from the platelet by the release reaction. The assays of these proteins were studied in patients with type I diabetes mellitus ( n = 30) and a healthy control group ( n = 15). Platelet factor 4 and β-thromboglobulin levels were not significantly different in both groups but thrombospondin concentrations in diabetic patients were significantly higher than those of the control group (136.6 ± 14.2 ng/ml vs 91.2 ± 14.3 ng/ml, P < 0.05). When the diabetic patients were divided into those with or without complications, the diabetic patients with complications ( n = 11) had significantly elevated plasma thrombospondin concentrations compared with the control group (150.4 ± 23.7 ng/ml vs 91.2 ± 14.3 ng/ml, P < 0.05), while thrombospondin concentrations in the control group were not statistically different from the diabetic patients without complications. Plasma β-thromboglobulin and platelet factor 4 levels were not significantly different between the diabetic and the control group. It is suggested that thrombospondin may be a convenient marker of in vivo platelet release reaction.

scholarly journals Type I diabetes mellitus decreases in vivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice

2011 ◽  
Vol 53 (3) ◽  
pp. 348-357 ◽  
Author(s):  
Jan Freark de Boer ◽  
Wijtske Annema ◽  
Marijke Schreurs ◽  
Jelske N. van der Veen ◽  
Markus van der Giet ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Reverse Cholesterol Transport ◽  
Type I Diabetes ◽  
Type I Diabetes Mellitus ◽  
Cholesterol Transport ◽  
Type I

Evaluation of α-klotho level in insulin dependent diabetes mellitus (IDDM) children

2020 ◽  
Vol 33 (6) ◽  
pp. 761-765
Author(s):  
Fariba Tarhani ◽  
Ghobad Heidari ◽  
Alireza Nezami
Keyword(s):  
Diabetes Mellitus ◽  
Type I Diabetes ◽  
Sandwich Elisa ◽  
Serum Levels ◽  
Dependent Diabetes Mellitus ◽  
Control Group ◽  
Case Group ◽  
Diabetic Patients ◽  
Type I ◽  
And Control

AbstractObjectivesReduced levels of α-Klotho is associated with the pathogenesis of various diseases including diabetes. In type I diabetes, decrease in Klotho leads to apoptosis of β-cells of pancreases. The aim of this study was to evaluate the levels of α-Klotho in type I diabetic pediatric patients.MethodsIn this cross-sectional single centered study, 46 patients presenting type I diabetes mellitus (case group) and 78 control group under the age of 12, referred to our clinic were included in our study. Serum levels of soluble Klotho were measured by sandwich ELISA in case and control groups. Statistical analysis was conducted for the data recorded via questionnaire.ResultsMean age of the patients in the case and control group was 7.65 ± 3.09 and 7 ± 2.37, respectively. Type I diabetes patients had a significant reduction in the levels of serum Klotho, as compared to controls (p<0.001). However, gender and age-based comparison between patient and control group was not significant.ConclusionsThis study reports a significant decrease in the serum levels of α-Klotho in type 1 diabetic patients. Low levels of Klotho can be associated with diabetic nephropathy and other comorbidities in these patients.

scholarly journals Triglycerides Predict Plasma Fibronectin in Children with Type I Diabetes Mellitus Rather than Diabetes

2002 ◽  
Vol 45 (1) ◽  
pp. 33-37 ◽  
Author(s):  
Ayşe Binnur Erbağcı ◽  
Mehmet Tarakçıoğlu ◽  
Ahmet Erbağcı ◽  
Mehmet Gözübüyük ◽  
Necat Yılmaz ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type I Diabetes ◽  
Plasma Cholesterol ◽  
Endothelial Activation ◽  
Type I Diabetes Mellitus ◽  
Control Group ◽  
Type I ◽  
Plasma Fibronectin ◽  
Diabetic Children ◽  
Adhesive Proteins

Fibronectins are adhesive proteins considered as markers of endothelial activation. Plasma fibronectin levels in diabetes mellitus (DM) have been found to be associated with atherosclerotic risk factors. This study was carried out to investigate plasma fibronectin and its relation with serum lipids, apolipoproteins AI, B100 and lp(a) in diabetic children. 35 children (19F/16M) with type I DM and 30 non-diabetic age and gender-matched controls were enrolled. Apolipoprotein and fibronectin concentrations were determined with nephelometric methods. Plasma fibronectin levels of the children with type I DM and the control group are not statistically different. HbA1c and triglycerides concentration are found to be significant predictors of plasma fibronectin in diabetic children, while effect of plasma cholesterol, apolipoprotein AI, B100 and lp(a) are insignificant. Diabetic children with triglycerides 1.13 mmol/l have elevated plasma fibronectin (median, 25th–75th percentiles; 29.6, 8.3–40.8 mg/dL) compared to the diabetic ≥19.9, 8.6–30.7 mg/dL, p<0,05) and non-diabetic children (16.6, 12.7–32.4 mg/dL, p<0.01) with triglycerides<1.13mmol/L. On the other hand plasma fibronectin concentrations of diabetic and non-diabetic children with high triglycerides are not significantly different. In conclusion our data does not support the concept that plasma fibronectin is elevated in type I diabetes mellitus at least in children, but high plasma triglycerides secondary to diabetes or not is associated with higher FNp concentrations which may have implications on atherogenesis. Plasma cholesterol, apolipoproteins AI, B100 and lp (a) are not significant determinants of FNp in type I diabetic children.

scholarly journals Clinical evaluation of complex treatment and prevention of generalized periodontitis in patients with type I diabetes mellitus with cardiomyopathy

2021 ◽  
Vol 25 (3) ◽  
pp. 424-427
Author(s):  
R. Y. Shkrebnyuk ◽  
V. T. Dyryk ◽  
O. M. Vynogradova ◽  
N. I. Bodnaruk ◽  
O. V. Zubachyk
Keyword(s):  
Diabetes Mellitus ◽  
Type I Diabetes ◽  
Type I Diabetes Mellitus ◽  
Control Group ◽  
Type I ◽  
Periodontal Tissue ◽  
Prevention Measures ◽  
Traditional Treatment ◽  
Periodontal Tissues ◽  
Treatment And Prevention

Annotation. Diabetes mellitus is an acute problem, as evidenced by the large number of people suffering from this disease, and the tendency to significantly increase the incidence rate. The most serious complications of diabetes include cardiomyopathy, the pathogenetic aspects of which are being actively studied. Widespread inflammatory-dystrophic periodontal disease and an increase in the proportion of generalized periodontitis in patients with diabetes mellitus complicated by cardiomyopathy, makes the problem of effective treatment and prevention of this pathology among the most relevant. The purpose of the study: clinical evaluation of complex treatment and prevention of generalized periodontitis in patients with type I diabetes mellitus with cardiomyopathy according to the developed algorithm. Comprehensive treatment and prevention measures were performed in 127 patients with generalized periodontitis on the background of type I diabetes mellitus with cardiomyopathy, of which 82 patients were the main group, where treatment was carried out using our proposed treatment and prevention algorithm. The control group, in which treatment was carried out according to protocol methods, consisted of 45 patients. Clinical visual examination and determination of paraclinical indices were performed on day 30 after treatment. Statistical calculation of digital values was performed on a Pentium II computer using the statistical software package “Statgraphic 2.3” and “Microsoft Excel 2000”, the significance of changes was evaluated by t-test. As a result of the research it was found that on average, 30 days after treatment, in the main group where we used the proposed pharmacotherapy, “normalization” of periodontal tissues was studied in 26.83 % of patients, “improvement” – in 30.49 % of patients’ treatment was ineffective in 42.68 % of patients, with a reliability of p>0.05. In patients of the control group, where traditional treatment and prevention measures were used to treat generalized periodontitis, on average, “normalization” of periodontal tissue was recorded in 17.78 % of patients, “improvement” of periodontal tissue was found in 28.89 % of patients. Treatment was ineffective in 53.33 % of patients. Thus, as a result of research, it can be argued that in patients with generalized periodontitis on the background of type I diabetes mellitus complicated by cardiomyopathy, whose treatment was carried out using our treatment and prevention algorithm, which included local measures and general appointments, significantly improved periodontal tissues, as confirmed by clinical observation. In the control group, where traditional treatment regimens were used, the treatment of generalized periodontitis was ineffective. In further studies, it is planned to study the microbiome of the oral cavity in patients with generalized periodontitis on the background of type I diabetes mellitus complicated by cardiomyopathy.

scholarly journals Divergent in vitro and in vivo lipid peroxidation in the postprandial phase of patients with type I diabetes mellitus

2007 ◽  
Vol 62 (3) ◽  
pp. 401-410 ◽  
Author(s):  
B Manuel-y-Keenoy ◽  
C de Vos ◽  
A van Campenhout ◽  
M Vinckx ◽  
P Abrams ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Lipid Peroxidation ◽  
Type I Diabetes ◽  
Type I Diabetes Mellitus ◽  
Type I ◽  
Postprandial Phase

Release of Erythrocyte-Derived ATP, a Recognized Stimulus of Nitric Oxide Production, Is Increased upon Incubation of Erythrocytes with C-Peptide.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1567-1567
Author(s):  
Dana M. Spence ◽  
Jennifer A. Meyer
Keyword(s):  
Nitric Oxide ◽  
Diabetes Mellitus ◽  
Type I Diabetes ◽  
Atp Release ◽  
Mechanical Deformation ◽  
Type I Diabetes Mellitus ◽  
No Production ◽  
Type I ◽  
C Peptide

Abstract Red blood cells (RBCs), when traversing microvascular beds, are subjected to mechanical deformation. It is established that RBCs release nanomolar to micromolar amounts of adenosine triphosphate (ATP), a recognized stimulus of nitric oxide (NO) production in vivo. The finding that ATP is released from RBCs in response to mechanical deformation, suggests that the RBC may be an important determinant of NO production as these cells traverse the intact circulation. An example of this potential importance of the RBC exists in diabetic complications. It is well established that patients with Type I diabetes mellitus, when compared to non-diabetics, have RBCs that are less deformable and more susceptible to oxidant stress. In conjunction with these findings, it has recently been reported that RBCs obtained from Type II diabetics release less ATP (91 +/− 10 nM) upon deformation than subjects without the disease (190 +/− 8 nM). These findings suggest that a membrane flexibilizer capable of increasing RBC-derived ATP in response to mechanical deformation may prove beneficial in improving microvascular flow. C-peptide, a 31 amino acid peptide, that connects the A and B chains of insulin, has been thought to have no significant biological role in vivo. Recently, it has been reported that C-peptide increases the deformability of erythrocytes obtained from the whole blood of patients with Type I diabetes mellitus. However, there has been no previous study to determine if C-peptide will actually increase the deformation-induced release of ATP from RBCs. Here, data is presented showing that adding nanomolar concentrations of C-peptide RBCs obtained from rabbits increases the ability of these cells to release ATP over time. When a 7% hematocrit of RBCs was incubated with a solution containing 6.6 nM C-peptide and pumped through tubing having an inside diameter that approximates resistance vessels in vivo (i.e., ~50 μm), the amount of ATP released from the RBCs increased from 0.246 ± 0.033 μM to 0.692 ± 0.140 μM (n = 10 rabbits, p<0.001) over a period of 8 hours. In the absence of the peptide, an aliquot from the same sample resulted in no significant increase in ATP release. Under conditions of non-flow, RBCs incubated with the peptide showed no statistically significant increase in ATP release. Additionally, RBCs that were incubated in the peptide containing 1 mM glybenclamide, a proven inhibitor of RBC-derived ATP, released 50% less ATP than a solution of RBCs in the absence of the inhibitor. Our results suggest that adding C-peptide to rabbit RBCs increases their ability to release ATP. Subsequent studies have shown the activity of C-peptide is depleted within 3–4 days after the solution is prepared. However, spectra obtained from a MALDI-TOF spectrometer clearly indicate that the peptide is still present in the solution exactly as it was on the day it was prepared. This suggests that there may be an activated form of the peptide that is responsible for the increase in RBC deformability and deformation-induced ATP release from these cells. In conclusion, these results suggest that C-peptide should not be considered as a biomarker alone and may have important interactions with RBCs in vivo.

The Values Of Platelet Factor 4 In Diabetic Patients Before And After The Isometric Exercise

1981 ◽  
Author(s):  
A Lučić ◽  
L Lepšanović ◽  
M Kulauzov ◽  
R Bukvić
Keyword(s):  
Platelet Activation ◽  
Isometric Exercise ◽  
Platelet Factor 4 ◽  
Diabetic Microangiopathy ◽  
Control Group ◽  
Diabetic Patients ◽  
Platelet Factor ◽  
Mean Values ◽  
The Mean

In order to evaluate the level of platelet activation in patients with the high risk for developing the thromboembolic complications and influence of isometric exercise on this process, the estimations of platelet factor 4 (PF 4) by the radioimmunoassay have been done in 20 diabetic patients. The half of examined patients had the diabetic microangiopathy as well as macroangiopathy (subgroup A) and the other half (subgroup B) had no clinical sign of macroangipathy. The control group comprises 10 healthy volunteers. The estimations of PF 4 have been done at rest and af ter 2 minutes isometric exercise. The mean values of PF 4 in both subgroups at the rest were significantly elevated in relation to the values in control group (sbg A = 92,7 ng/ml, sbg B = 44,05 ng/ml and control 7,91 ng/ml). After the isometric exercise the mean values of PF 4 in diabetics have been moderately decreased (sbg A = 69,01 ng/ml, sbg B = 39,2 ng/ml), but increase in relation to mean values in control group (24,2 ng/ml). The results indicate the high degree of in vivo platelet activation in diabetic patients, especially in those with macroangiopathic changes. The isometric exercise in the mean time, did not effect the platelet release reaction in examined patients.

The effect of pirenzepine on growth hormone and blood glucose levels in Type I diabetes mellitus

1988 ◽  
Vol 117 (3) ◽  
pp. 315-319 ◽  
Author(s):  
P. Pietschmann ◽  
G. Schernthaner
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Type I Diabetes ◽  
Anticholinergic Drug ◽  
Serum Levels ◽  
Type I Diabetes Mellitus ◽  
Diabetic Patients ◽  
Type I ◽  
Glucose Levels ◽  
Blood Glucose Levels

Abstract. Increased GH levels in Type I diabetes mellitus have been implicated in the pathogenesis of metabolic complications such as the so-called dawn phenomenon. GH secretion is under control of cholinergic mechanisms. In 21 Type I diabetic patients the effect of oral administration of the anticholinergic drug pirenzepine in addition to intensive insulin therapy on GH and blood glucose levels was studied. At 21.30, 08.00 and 12.00 h, all patients received in random order 50 mg of pirenzepine or placebo po. Blood for determination of GH, blood glucose, cortisol and Cpeptide levels were obtained at 3-h intervals. Serum levels of plasma glucose and GH were significantly lower under pirenzepine than under placebo (P < 0.05 and P < 0.01, respectively). Serum levels of cortisol, free insulin and C-peptide were comparable on the test and the control day. Our data indicate that in Type I diabetes mellitus the anticholinergic drug pirenzepine is effective in decreasing both GH and blood glucose levels.

Detection of Enhanced In Vivo Platelet α-Granule Release in Different Patient Groups - Comparison of β-Thromboglobulin, Platelet Factor 4 and Thrombospondin Assays

1984 ◽  
Vol 52 (02) ◽  
pp. 183-187 ◽  
Author(s):  
D A Lane ◽  
H Ireland ◽  
S Wolff ◽  
E Ranasinghe ◽  
J Dawes
Keyword(s):  
Platelet Factor 4 ◽  
Renal Elimination ◽  
Elevated Plasma ◽  
Platelet Factor ◽  
Release Reaction ◽  
Heparin Anticoagulation ◽  
Patient Groups ◽  
Granule Release ◽  
Sensitive Marker

SummaryDuring the platelet release reaction β-thromboglobulin (βTG), platelet factor 4 (PF4) and thrombospondin (TSP) are released from the platelet into plasma and assays of these proteins can be used to monitor in vivo platelet activation. We have assessed their relative merits as markers of the in vivo platelet α-granule release reaction in a number of patient groups which have previously been shown to have elevated plasma βTG and/or PF4 levels. It is concluded that in diseases or conditions not complicated by its reduced clearance, βTG is the most sensitive marker of in vivo platelet α-granule release. However, the TSP assay may be the least ambiguous when monitoring the platelet α-granule release reaction in patients with renal failure who are undergoing haemodialysis with heparin anticoagulation. Under these circumstances plasma βTG, but not PF4 or TSP, levels are elevated because of impaired renal catabolism, and the presence of a heparin-releasable reservoir of PF4 on the endothelium complicates the use of the PF4 assay. In liver failure none of these assays may accurately reflect platelet α-granule release because of impaired hepatic or renal elimination of the proteins.

Sign in / Sign up

Export Citation Format

Share Document